Literature DB >> 21150213

Molecular study of proteinuria in patients treated with B₁₂ supplements: do not forget megaloblastic anemia type 1.

Nomy Levin-Iaina1, Dganit Dinour, Gabriel Morduchowicz, Liat Ganon, Eli J Holtzman.   

Abstract

BACKGROUND/AIMS: Current consensus supports the notion that proteinuria is a marker of renal disease with prognostic implications. Whereas most chronic kidney disease patients with proteinuria would often require antiproteinuric agents, there are some exceptions. Megaloblastic anemia type 1 (MGA1) is characterized by megaloblastic anemia due to congenital selective vitamin B(12) malabsorption and proteinuria. In the present study, we describe 2 Israeli Jewish patients with MGA1 and isolated proteinuria.
METHODS: Because of their origin, the patients were screened for the presence of the already studied Tunisian AMN mutation, by direct sequencing the corresponding region from genomic DNA. PCR products were purified and sequenced.
RESULTS: Genomic DNA sequencing of the AMN gene of both patients confirmed that the acceptor splice site in intron 3 was changed from CAG to CGG (208-2A→G).
CONCLUSION: We determined the molecular basis of MGA1 in both patients and discuss the involvement of the cubilin/AMN complex in this pathology and its role in the development of the proteinuria. We also discuss the questionable significance of antiproteinuric treatment for these patients.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21150213     DOI: 10.1159/000320391

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  2 in total

1.  Novel compound heterozygous mutations in AMN cause Imerslund-Gräsbeck syndrome in two half-sisters: a case report.

Authors:  Emma Montgomery; John A Sayer; Laura A Baines; Ann Marie Hynes; Virginia Vega-Warner; Sally Johnson; Judith A Goodship; Edgar A Otto
Journal:  BMC Med Genet       Date:  2015-06-04       Impact factor: 2.103

2.  Detailed investigations of proximal tubular function in Imerslund-Gräsbeck syndrome.

Authors:  Tina Storm; Christina Zeitz; Olivier Cases; Sabine Amsellem; Pierre J Verroust; Mette Madsen; Jean-François Benoist; Sandrine Passemard; Sophie Lebon; Iben Møller Jønsson; Francesco Emma; Heidi Koldsø; Jens Michael Hertz; Rikke Nielsen; Erik I Christensen; Renata Kozyraki
Journal:  BMC Med Genet       Date:  2013-10-24       Impact factor: 2.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.